Abstract:Polymer drug conjugates have demonstrated application potentials in optimizing chemotherapeutics. In this study a new bioconjugate, HA-ss-PTX, was designed and synthesized with cooperative dual characteristics of active tumor targeting and selective intracellular drug release. Paclitaxel (PTX) was covalently attached to hyaluronic acid (HA) with various sizes (MW 9.5, 35, 770 kDa); a cross-linker containing disulfide bond was also used to shield drug leakage in blood circulation and to achieve rapid drug release in tumor cells in response to glutathione. Incorporation of HA to the conjugate enhanced the capabilities of drug loading, intracellular endocytosis and tumor targeting of micelles in comparison to mPEG. HA molecular weight showed significant effect on properties and antitumor efficacy of the synthesized conjugates. Intracellular uptake of HA-ss-PTX toward MCF-7 cells was mediated by CD44-caveolae-mediated endocytosis. Compared to Taxol and mPEG-ss-PTX, HA9.5-ss-PTX demonstrated improved tumor growth inhibition in vivo with a TIR of 83.27 +/- 5.20%. It was concluded that HA9.5-ss-PTX achieved rapid intracellular release of PTX and enhanced its therapeutic efficacy, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics.Statement of SignificancePolymer drug conjugates, promising nanomedicines, still face some technical challenges including a lack of specific targeting and rapid intracellular drug release at the target site. In this manuscript we designed and constructed a novel bioconjugate HA-ss-PTX, which possessed coordinated dual characteristics of active tumor targeting and selective intracellular drug release. Redox-responsive disulfide bond was introduced to the conjugate to shield drug leakage in blood circulation and to achieve rapid drug release at tumor site in response to reductant like glutathione. Paclitaxel was selected as a model drug to be covalently attached to hyaluronic acid (HA) with various sizes to elucidate the structure activity relationship and to address whether HA could substitute PEG as a carrier for polymeric conjugates. Based on a series of in vitro and in vivo experiments, HA-ss-PTX performed well in drug loading, cellular internalization, tumor targeting by entering tumor cells via CD44-caveolae-mediated endocytosis and rapidly release drug at target in the presence of GSH. One of the key issues in clinical oncology is to enhance drug delivery efficacy while minimizing side effects. The study indicated that this new polymeric conjugate system would be useful in delivering anticancer agents to improve therapeutic efficacy and to minimize adverse effects, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

The Development of Peptide-Drug Conjugates (pdcs) Strategies for Paclitaxel

A Dual Bispecific Hydrolysis Peptide-Drug Conjugate Responsive to Micro-Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple-Negative Breast Cancer

Peptide-drug conjugates: A new paradigm for targeted cancer therapy

Identification of a pH-Responsive Peptide-Paclitaxel Conjugate as a Novel Drug with Improved Therapeutic Potential.

Peptide Drug Conjugates and Their Role in Cancer Therapy

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic

Well-defined Polymer-Drug Conjugate Engineered with Redox and Ph-Sensitive Release Mechanism for Efficient Delivery of Paclitaxel.

A Sulfobetaine Zwitterionic Polymer-Drug Conjugate For Multivalent Paclitaxel And Gemcitabine Co-Delivery

Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).

Drug content on anticancer efficacy of self-assembling ketal-linked dextran-paclitaxel conjugates

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Peptide-Drug Conjugate: A Novel Drug Design Approach

Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer

Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges

Paclitaxel-Paclitaxel Prodrug Nanoassembly As A Versatile Nanoplatform for Combinational Cancer Therapy

Controlled Release Strategy of Paclitaxel by Conjugating to Matrix Metalloproteinases-2 Sensitive Peptide.

Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.

Co-Delivery of Paclitaxel by a Capsaicin Prodrug Micelle Facilitating for Combination Therapy on Breast Cancer

Intracellular Delivery and Antitumor Effects of a Redox-Responsive Polymeric Paclitaxel Conjugate Based on Hyaluronic Acid.

Polypeptide-based Combination of Paclitaxel and Cisplatin for Enhanced Chemotherapy Efficacy and Reduced Side-Effects.

Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency